ArticleNature nanotechnology2025
A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy.
Article in Nature nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- GSH-responsive nanovaccine triggers immunogenic cell death and potent memory T cell immunity for durable, recurrence-free tumor eradication.Bioactive materials · 2026Article
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- Disrupting fumarylacetoacetate hydrolase by stratified nanoplatforms orchestrates metabolic-immune reprogramming and prevents post-ablation HCC relapse.Nature communications · 2026Article
- Switching tumor-derived extracellular vesicles off and on via targeted proteolysis to shift toward immunogenic phenotypes.Signal transduction and targeted therapy · 2026Article
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy.Cell reports. Medicine · 2026Article
- Self-fueling catalysis-driven membrane destabilization triggers CSC-enriched tumors ablation.Journal of nanobiotechnology · 2026Article
- Folic acid-modified antigen-trapping nanoprobes for developing in situ tumor vaccines to inhibit metastasis and recurrence of ovarian cancer.Journal of nanobiotechnology · 2026Article
- Advances in Nanotechnology-Based Topical Delivery Systems for Skincare Applications.Pharmaceutics · 2026Review
- Nanomedicines Reshape the Tumor Microenvironment: Multidimensional Strategies from Modulating "Barriers" to Metabolic Intervention.International journal of nanomedicine · 2026Review
- Dendritic cells in cancer immunotherapy: functional barriers, reprogramming strategies and translational challenges.Frontiers in immunology · 2026Review
- Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.International journal of nanomedicine · 2026Review
- Biomimetic Cell Membrane-coated Nanovaccines in Anti-tumor Immunotherapy.Theranostics · 2026Review
- Turning cold tumors into hot tumors to ignite immunotherapy.Molecular cancer · 2025Review
- A magnetically programmable mesoporous nanoreactor.Nature nanotechnology · 2025Article
- Novel strategies for nanovaccine application in breast cancer treatment.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Residual cancer stem-like cells (CSCs) can cause tumour recurrence within a narrow margin around the initial tumour resection lesion, increasing the risk of post-surgical relapse and incurability. Currently, there are no efficient strategies for tracking and eradicating CSCs. Here we propose a nanovaccine strategy, called NICER, based on a nanovesicle system integrating CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer, to simultaneously eradicate CSCs and bulk tumour cells. Specifically, nanovesicles derived from aldehyde-dehydrogenase-overexpressing tumours could serve as integrated antigens carrying both CSC-specific antigen and tumour-associated antigen. Epigenetic nano-regulator targeting YTH N
Indexed as
Identifiers
40523938What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.